Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cardiovascular mortality in schizophrenia: defining a critical period for prevention.

Srihari VH, Phutane VH, Ozkan B, Chwastiak L, Ratliff JC, Woods SW, Tek C.

Schizophr Res. 2013 May;146(1-3):64-8. doi: 10.1016/j.schres.2013.01.014. Epub 2013 Feb 17.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?

Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, Srihari VH.

Schizophr Res. 2011 Apr;127(1-3):257-61. doi: 10.1016/j.schres.2010.12.008. Epub 2011 Jan 15.

4.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
5.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
7.

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST study group.

Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95. doi: 10.1017/S1461145712001241. Epub 2012 Dec 20.

PMID:
23253821
8.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR.

J Clin Psychiatry. 2010 Mar;71(3):304-11. doi: 10.4088/JCP.08m04718yel. Epub 2010 Jan 12.

9.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
10.

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.

Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Schizophr Res. 2008 Sep;104(1-3):1-12. doi: 10.1016/j.schres.2008.05.009. Epub 2008 Jul 7.

PMID:
18606526
11.

[Vigilance level for cardiovascular risk factors in schizophrenic patients].

Rouillon F, Van Ganse E, Vekhoff P, Arnaud R, Depret-Bixio L, Dillenschneider A.

Encephale. 2015 Feb;41(1):70-7. doi: 10.1016/j.encep.2014.12.003. Epub 2015 Jan 27. French.

PMID:
25637197
12.

Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C.

Psychosomatics. 2013 Jan-Feb;54(1):67-73. doi: 10.1016/j.psym.2012.03.001. Epub 2012 Jun 2.

13.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
14.

Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.

Jerrell JM, McIntyre RS, Tripathi A.

Clin Schizophr Relat Psychoses. 2010 Oct;4(3):161-8. doi: 10.3371/CSRP.4.3.2.

PMID:
20880826
15.
16.

Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.

Said MA, Sulaiman AH, Habil MH, Das S, Bakar AK, Yusoff RM, Loo TH, Bakar SA.

Singapore Med J. 2012 Dec;53(12):801-7.

17.

Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.

Deuschle M, Paul F, Brosz M, Bergemann N, Franz M, Kammerer-Ciernioch J, Lautenschlager M, Lederbogen F, Roesch-Ely D, Weisbrod M, Kahl KG, Reichmann J, Gross J, Umbreit J.

Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1283-8. doi: 10.1007/s00127-013-0676-0. Epub 2013 Mar 21.

PMID:
23515714
18.

Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort.

Bobes J, Arango C, Garcia-Garcia M, Rejas J.

Schizophr Res. 2010 Jun;119(1-3):101-9. doi: 10.1016/j.schres.2010.02.1030. Epub 2010 Mar 9.

PMID:
20219322
19.

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN.

Br J Psychiatry. 2007 Jul;191:23-9.

20.

Twenty-year trends in cardiovascular risk factors in India and influence of educational status.

Gupta R, Guptha S, Gupta VP, Agrawal A, Gaur K, Deedwania PC.

Eur J Prev Cardiol. 2012 Dec;19(6):1258-71. doi: 10.1177/1741826711424567. Epub 2011 Sep 26.

PMID:
21947630
Items per page

Supplemental Content

Write to the Help Desk